At Vyant Bio our human-powered approach to drug discovery maximizes the likelihood of clinical success. By integrating human-based microOrgan® technology, state-of-the-art engineering, advanced data science, regulatory rigor, and a deep personal commitment to the field, we accelerate and de-risk the process—identifying, with greater predictive value, the most viable, safe, and effective drug candidates capable of transforming lives.
Vyant Bio’s dynamic drug discovery engine is powered by a convergence of innovative bioengineering technologies, industry-leading data science, and world-class IND-enabling development strategies—seamlessly coordinated in one reliable resource.
Our powerful AnalytiX™ platform, at the intersection of human biology and machine learning, is unmatched in its ability to quickly and comprehensively analyze robust functional data to identify the most promising drug candidates, targets, and biomarkers via a quantified, unbiased rank order approach.
Our proprietary microOrgan technology uses functional microtissues engineered from induced pluripotent stem cells (iPSC) to facilitate high-throughput, human-based drug discovery without the risks or delayed timing of testing drugs in humans. As a result, we gain disease and biologic insights earlier than thought possible—in the lab rather than in the clinic.
We are passionately committed to advancing drug discovery success, from ID to IND, by harnessing state-of-the-art science, technology, data analytics, and regulatory rigor across our global footprint—to improve patient lives—while remaining human throughout the process.
Take a deeper dive into our discovery capabilities by visiting our subsidiaries’ websites.
Learn more about our unique microOrgan® technology and how it can accelerate drug discovery.
Find out more about our IND-enabling, world-class late-stage preclinical in vivo testing capabilities.